Trial Profile

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary) ; Tremelimumab (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use

13 Jul 2026 Planned number of patients changed from 70 to 86.
15 Dec 2025 Planned End Date changed from 30 Nov 2025 to 30 Dec 2026.
15 Dec 2025 Planned primary completion date changed from 30 Nov 2025 to 30 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com